Therapeutic vaccination with an EGF-based vaccine in lung cancer: A step in the transition to a chronic disease

Expert Review of Respiratory Medicine

Volumn 5, Issue 3, 2011, Pages 337-342

  Rodriguez, Gryssell ^a   Gonzalez, Gisela ^a   Crombet, Tania ^b   Lage, Agustin ^b  

^a CIMAB SA   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

cancer vaccine; EGF EGFR binding inhibition; epidermal growth factor; immunotherapy; lung cancer

Indexed keywords

ALUMINUM HYDROXIDE; CANCER VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTARALDEHYDE; MONTANIDE ISA 51; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT P64K PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE PAIN; CANCER IMMUNIZATION; CANCER SURVIVAL; CHILL; CHRONIC DISEASE; DIZZINESS; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EHRLICH ASCITES TUMOR; FLUSHING; HOT FLUSH; HUMAN; HYPERTENSION; IMMUNOGENICITY; INJECTION SITE PAIN; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; NAUSEA; NEISSERIA MENINGITIDIS; NONHUMAN; PROTEIN BLOOD LEVEL; SIDE EFFECT; TUMOR IMMUNITY; VOMITING; XEROSTOMIA;

EID: 79959742758     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.12     Document Type: Article

References (20)

1. Jemal A, Siege R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010
2. Bunn PA Jr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J. Clin. Oncol. 20(18s), 23-33 (2002
3. Gerard C, Debruyne C. Immunotherapy in the landscape of new targeted targeted treatments for non-small cell lung cancer. Mol. Oncol. 3(5-6), 409-429 (2009
4. Lage A, Crombet T, González G. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. Ann. Med. 35, 327-336 (2003 (Pubitemid 37013673)
5. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicenter, randomized, placebo-controlled study. Lancet Oncol. 11(6), 521-529 (2010
6. Mitsudomi TMD, Morita S, Yatabe Y et al.Genfitinib versus cisplatin plus docetaxel in patients with no-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized Phase 3 trial. Lancet Oncol. 11(2), 121-128 (2010
7. González G, Lage A. Cancer vaccines for hormone immune-deprivation: the EGF vaccine approach. In: Leading Topics in Cancer Research (Chapter 11NOVA Publishers, Inc., NY, USA, 293-310 (2007
8. Gonzalez G, Pardo OL, Sanchez B et al. Induction of immune recognition of self-epidermal growth factor II: characterization of antibody response and use of a fusion protein. Vaccine Res. 6(2), 91-100 (1997 (Pubitemid 27499903)
9. González G, Sánchez B, Suárez E et al. Induction of immune recognition of self epidermal growth factor (EGF): effect on EGF - biodistribution and tumor growth. Vaccine Res. 4, 233-244 (1996 (Pubitemid 27089202)
10. Montero E, Valdes M, Lopez A, Perez R, Lage A. Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor based cancer vaccine. Vaccine 27, 2230-2239 (2009
11. Rodriguez PC, Gonzalez I, Gonzalez A et al. Priming and boosting determinants on the antibody response to epidermal growth factor-based cancer vaccine. Vaccine 26, 4647-4654 (2008
12. Casacó A, Díaz Y, Ledón N et al. Effect of an EGF cancer vaccine on wound healing and inflammation models. J. Surg. Res. 122, 130-134 (2004 (Pubitemid 39441243)
13. Gonzalez G, Crombet T, Catala M et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol. 9(4), 431-435 (1998 (Pubitemid 28273037)
14. Gonzalez G, Crombet T, Torres F et al. Epidermal growth factor-based cancer vaccine for non-small cell lung cancer therapy. Ann. Oncol. 14, 461-466 (2003 (Pubitemid 36367426)
15. Crombet T, Neninger E, Catalá M et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol. Ther. 5(2), 145-149 (2006
16. González G, Crombet T, Neninger E, Viada C, Lage A. Therapeutic vaccination with epidermal growth factor/EGF in advanced lung cancer: analysis of pooled data from three clinical trials. Hum. Vaccin. 3(1), 8-13 (2007
17. Neninger E, de la Torre A, Osorio M et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell-lung cancer. J. Clin. Oncol. 26 (9), 1452-1458 (2008)
18. Neninger E, García B, Crombet T et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced non small cell lung cancer. J. Immunotherapy 32, 92-99 (2009
19. García B, Neninger E, de la Torre A et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin. Cancer Res. 14(3), 840-846 (2008 (Pubitemid 351231168)
20. Gonzalez G, Crombet T, Lage A. Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving long lasting treatment. Curr. Cancer Drug Targets 11(1), 103-110 (2010).